Get a fuller health picture alongside acne treatment
Membership includes 100+ biomarkers in a single draw, including hormone markers.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
At a glance
- Clascoterone (brand name Winlevi) is the first topical anti-androgen approved for acne, cleared by the FDA in 2020.
- It blocks androgen receptors in the skin, so it can be used by both males and females without the body-wide hormonal effects of pills taken by mouth.
- In two phase 3 trials, clascoterone cream raised the rate of clear or almost clear skin compared with vehicle over 12 weeks.
- It is applied twice daily, and benefit continued to increase with use over several months.
- Evidence strength: Moderate, based on large randomized trials and a meta-analysis, though it is newer and long-term real-world data are still building.
What is clascoterone?
Clascoterone is a topical cream that targets androgen receptors in the skin. Androgens are hormones that drive oil production and clogged pores, and most anti-androgen acne treatments, such as spironolactone or birth control pills, work throughout the body. Clascoterone is different because it acts locally in the skin with limited systemic hormonal effects, which is why it became the first topical of its kind approved for acne when the FDA cleared it in 2020.
What skin type is clascoterone best for?
Clascoterone suits people with moderate acne that has a hormonal pattern, including oily skin and breakouts along the lower face and jaw. Because it works at the androgen receptor in the skin rather than in the bloodstream, it can be used across genders, which sets it apart from oral anti-androgens that are generally limited to women. Trials enrolled people with both inflammatory and non-inflammatory lesions, so it can fit a range of acne types.
What does clascoterone treat?
Clascoterone is approved for acne vulgaris in people aged 12 and older. In two identical phase 3 trials, treatment success reached about 18-20% with clascoterone versus 7-9% with vehicle at 12 weeks, with reductions in both inflamed and non-inflamed lesions. A meta-analysis of randomized trials found it significantly improved acne severity scores with a safety profile similar to vehicle. It targets one of the root drivers of acne, oil production, rather than only treating bacteria or inflammation.
How do you know if clascoterone can help your skin?
Clascoterone is worth discussing with a prescriber if you have oily, hormone-related acne, or if you want an anti-androgen approach but cannot or prefer not to take oral medication. It is also an option for men who want anti-androgen treatment, since oral versions are not used in males. Because results built gradually and kept improving over up to 12 months of use, it suits people ready to use it consistently rather than expecting a quick change.
How do you use clascoterone?
Apply a thin layer to the affected skin twice a day, in the morning and evening, on clean dry skin. In the trials it was applied twice daily for 12 weeks and then longer in an extension study. Give it time, since lesion counts in studies kept falling past the first few weeks. If your skin feels dry, a light non-comedogenic moisturizer can help, and you can use it alongside other acne treatments your prescriber recommends.
What are the potential side effects of clascoterone?
Clascoterone is generally well tolerated. The most common issues are mild local skin reactions, especially trace or mild redness and some dryness or scaling at the application site. In pooled safety data, rates of side effects were similar to vehicle, with no meaningful difference in serious events.
Because so little reaches the bloodstream, the hormonal side effects seen with oral anti-androgens are not expected, though some early studies checked blood hormone and potassium values as a precaution. This is general information rather than medical advice, so follow your prescriber's guidance.
Evidence strength
Moderate: Clascoterone is supported by two large phase 3 randomized trials, a long-term extension, and a meta-analysis, all showing benefit over vehicle with a favorable safety profile. The main caveats are that treatment success rates at 12 weeks were modest in absolute terms, it is a newer drug approved in 2020 so long-term real-world experience is still accumulating, and few trials compare it directly against established topicals. In practice it is often used as part of a broader routine, and consistent twice-daily use matters for results.
References
- Smith CA, Gosnell E, Karatas TB, Deitelzweig C, Collins EMB, Yeung H. Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists. Dermatology and Therapy. 2025;15(1):45-59. doi:10.1007/s13555-024-01324-8
- Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne. JAMA Dermatology. 2020;156(6):621. doi:10.1001/jamadermatol.2020.0465
- Eichenfield LF, Gold LS, Han J, et al. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris. Journal of Drugs in Dermatology. 2024;23(1):1278-1283. doi:10.36849/JDD.7719
- Alkhodaidi ST, Al Hawsawi KA, Alkhudaidi IT, Magzoub D, Abu‐Zaid A. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Dermatologic Therapy. 2021;34(1). doi:10.1111/dth.14609
















